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Abstract
Background: Assessment of health-related quality of life (HRQoL) is well established in clinical 
research, but ceiling effects in validated tools might prevent detection of changes in well respond-
ents. Tobacco Quality of Life Impact Tool (TQOLITv1) uses conceptual and psychometric advances 
to enhance detection of HRQoL changes.
Methods: In a 6-month, forced-switch study, the German TQOLITv1 was assessed in healthy adult 
(age 23–55 years) current and matched former-smokers. At baseline, smokers were switched to 
reduced toxicant prototype (RTP) or conventional cigarette for 6 months. TQOLITv1 responses were 
collected at baseline, 3 and 6 months from current smokers whilst former smokers completed it 
at the latter two time points. TQOLITv1 includes SF-36v2 and new smoking-specific, physical and 
general-health measures.
Results: Reliability at baseline was good (Cronbach’s coefficient alpha > 0.70) for all measures. The 
baseline percentage with the best possible score (ceiling effect) for former and current smokers was 
substantially better for the new physical function than SF-36 physical function measure (35% vs. 59% 
at ceiling, respectively). New smoking-specific measures discriminated current from former smokers 
better than general health measures. Smoking-specific symptoms (r = 0.73) were more stable from 
baseline to 6 months than other measures (r = 0.38–0.54) particularly more than the SF-36 mental 
component score (r = 0.24). Although both product smoking groups worsened in most HRQoL meas-
ures, changes in general and smoking-specific HRQoL impact measures favored RTP smokers.
Conclusions: The German TQOLITv1 is sufficiently reliable and valid to assess HRQoL and may be 
more useful than SF-36v2 in evaluation of interventions in well smoking populations including 
those consuming RTPs.
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Introduction
Health-related quality of life (HRQoL) is an established multidi-
mensional concept with a well-defined framework for qualifying 
measures used in clinical trials.1 HRQoL assessments have gained 
importance in clinical research, routine health care, and regulatory 
review of medical interventions. The SF-36v2 general health sur-
vey has been widely used in clinical trials2 and in tobacco research 
mostly to differentiate HRQoL between current, former, and never 
smokers.3–6 Considerations related to whether some of the harm 
caused by tobacco products might be reduced with modified-risk 
tobacco products (MRTPs) have led the US Institute of Medicine 
(IOM) and Food and Drug Administration to consider the optimum 
study designs for their assessment.7 The IOM in its report, Scientific 
Studies on MRTPs8 considers HRQoL among other scientific evi-
dence in providing guidance for evaluation of MRTP impact on 
public health.
The concept of MRTPs (initially referred to as potential 
reduced-exposure products) was introduced by the IOM in its 2001 
report, Clearing the Smoke: the Scientific Basis for Tobacco Harm 
Reduction.9 Potential reduced-exposure products were defined as 
products that would substantially reduce exposure to one or more 
tobacco toxicants and could reasonably be expected to reduce the 
risk of one or more smoking-related diseases or other adverse health 
effects. Surveillance for smoking-related diseases and construction of 
aggregate measures of population health impact, including HRQoL, 
were suggested. In 2009, the Family Smoking Prevention and 
Tobacco Control Act10 gave the US Food and Drug Administration 
the authority to regulate all tobacco products to a population-based 
health standard, and the IOM advocated that composite outcomes 
would most accurately reflect general-health outcomes, in the same 
way that self-reported health status and disability-adjusted life years 
summarize health.8 So far only draft guidance on MRTP research is 
available.11
Validated HRQoL instruments, such as SF-36v2, SF-6D, and 
EQ-5D12 are widely used to contribute to important health-care 
decisions, but they generally have broad applications. The lack of 
measures specific to tobacco-related HRQoL potentially limits the 
usefulness of these tools in tobacco research. In a clinical study of 
reduced toxicant prototype (RTP) versus conventional cigarettes, the 
SF-36v2 general health survey was used by Shepperd and colleagues 
to explore the impact of switching to RTP in healthy smokers, as a 
secondary outcome.13 Primary outcomes such as some vapor-phase 
toxicants and particulate-phase toxicants were shown to be reduced 
in RTP smokers by biomarker assessment. However, unpublished 
SF-36v2 data from this study identified ceiling effects (ie, large pro-
portions of respondents earning the best possible score), particularly 
for measures of physical functioning (49.6%), role-physical (62.5%), 
role-emotional (63.3%), and social functioning (74.1%).14 Similarly, 
a study of current (n = 77) and former (n = 24) smokers also identi-
fied ceiling effects on these four SF-36 scales.4 Instruments with ceil-
ing effects cannot detect improvements in scores outside the range 
measured. Additionally, as suggested by a review of the literature and 
two publically available databases,14 positive health domains such as 
confidence in health and psychological well-being have not been the 
focus of tobacco-related research and might be better in discriminat-
ing between smoking and nonsmoking populations in comparison 
with other widely-used general HRQoL instruments.
Most clinical studies of exposure to tobacco toxicants enroll 
smokers with good health status.15–17 This approach seems appro-
priate to assess the performance of MRTPs before they reach the 
market. However, to obtain robust data on changes in HRQoL in 
healthy tobacco users, improving the measurement range to raise the 
“ceiling” is an issue of importance, clinically, socially, and economi-
cally. The magnitude of change that is relevant for measures that 
raise the ceiling scores in healthy populations (ie, considered as a 
minimal important difference (MID) must be determined to support 
interpretation of impact of modified tobacco or nicotine products.
The Tobacco Quality of Life Impact Tool (TQOLIT™v1) was 
designed on the basis of end-point models that integrate clinical and 
HRQoL outcomes18 as recommended for the regulatory review of new 
drugs, to overcome measurement issues with legacy tools.1 The con-
ceptual framework of TQOLITv1 takes into account clinical param-
eters, new smoking-specific measures (both symptoms and impact on 
HRQoL attributable to smoking) and general health (Supplementary 
Appendix 1). The advantages of disease-specific measures have been 
achieved by focusing on specific symptoms such as smokers cough. 
Conceptually, however, this is not enough. Specific symptoms are not 
HRQoL because they do not capture and broadly represent life or its 
quality in terms of what people are able to do or how they feel. Life is 
affected to the extent that symptoms are severe enough to limit func-
tional activities and how people feel in everyday life. For this reason, 
TQOLIT also measures the impact attributed to smoking in every-
day life. The conceptual framework places emphasis on the sequence 
of events that occur in relation to changing smoking behaviors, that 
is, toxicant exposure may cause changes in clinical parameters that 
could result in symptoms, all of which eventually have an impact 
on HRQoL attributed to smoking and also general health outcomes. 
Advanced psychometric methods19,20 have been used to increase the 
range over which reliable scores can be measured, particularly ceiling 
scores, to enhance detection of HRQoL changes in healthy smok-
ers. A certified German translation of the TQOLITv1 was prepared 
(see Methods below) and was administered for the first time in a 
6-month clinical study of healthy current, former and never smok-
ers.21 TQOLIT was a secondary outcome in that study making it pos-
sible to evaluate the psychometric performance (reliability, validity 
and stability) of previously used and new TQOLITv1 measures. Here 
we report validation tests of these measures and explore the ability 
of the instrument to detect changes in smokers HRQoL over time.
Methods
Study Design and Participants
The study was a single-center, single-blind, controlled clini-
cal study with a forced-switching design that was conducted in 
Hamburg, Germany. The study was approved by the independent 
ethics committee of the Ärztekammer, Hamburg and registered 
(ISRCTN81286286). Participants were enrolled after they responded 
to advertisements in the local media and on the clinic’s website. All 
participants were informed about the design and purpose of the 
study verbally and in writing, and all gave written informed con-
sent which had information on the ethically approved stipend for 
participation.
Sample size calculations were based on the primary endpoints of 
the study (ie, biomarkers of exposure) using data from a previous 
RTP study.13 Sample size was calculated using MINITAB software 
version 15 and based on one-way analysis of variance. These calcula-
tions indicated that a sample size of 50 yielded at least an 80% power 
for all biomarkers of exposure included. A level of attrition during 
this longitudinal study was assumed and therefore 140 healthy adult 
current smokers of cigarettes with 6–8 mg International Organization 
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for Standardization tar yields were recruited. This smoking group was 
later split into approximately equivalent test and control groups, each 
group with a sample size of approximately 70. In addition, 60 healthy 
adult ex-smokers were recruited. The slight reduction in ex-smokers 
compared to smokers group sizes were based on an assumption that 
attrition would be lower for the non-smoking groups.
Participants underwent medical screening to ensure compliance 
with protocol inclusion and exclusion criteria.21 As a result 128 
smokers and 58 ex-smokers were eligible for enrolment. Smokers 
were aged 23–55  years and ex-smokers 28–55  years. These study 
samples were deemed adequate for the evaluations of TQOLITv1 
with methods used in previous psychometric evaluations.22,23 Current 
smokers had to have smoked regularly for at least 5 years smoking 
from the minimum legal smoking age in Germany (18 years). Former 
smokers had to have quit for at least 5 years after having smoked for 
at least 5 years. Participants were recruited and groups filled accord-
ing to order of screening, age, gender, and availability at the start of 
the study, and the demographics for all groups were matched as far 
as possible. To ensure that enough participants were recruited to all 
groups, participant availability was assured, and groups were well 
matched for age and gender, full randomization was not possible. 
During the first 2 weeks, all smokers were supplied with a control 
conventional cigarette typical of products widely sold at the time. 
Numbers of cigarettes supplied were based on self-reported daily 
consumption at screening, plus two packs. Participants were not told 
at screening that their supply of cigarettes were free or would be 
based on their self-reported consumption. On Day 14 (baseline), half 
of smokers were switched to the RTP and half continued to smoke 
the control product for the remainder of the study. Smokers were 
allowed to smoke ad libitum and were asked to record daily con-
sumption in electronic diaries every day for the duration of the study.
TQOLITv1 Modules, Administration, and Scoring
The survey modules in TQOLITv1 covered demographics and 
smoking-specific and general HRQoL measures. The new smoking-
specific measures included symptoms and HRQoL impact attributed 
to smoking. New general measures included improved physical func-
tioning and general health (GH) confidence measures (Table 1). For 
example, in contrast to SF-36v2 items, which define perfect physical 
health as the absence of limitations in physical activities, new items 
also measured how easy it was to perform them, in order to raise 
the ceiling. Further, evaluations of health in general (eg, excellent to 
poor) were expanded to include “confidence” in health at present 
and in the future in order to broaden that construct (Table 1). Other 
general measures administered included the eight health domains in 
the SF-36v2 as administered in previous studies. TQOLITv1 includes 
certified German-language translations. The SF-36 was translated 
using International Quality of Life Assessment Project methods.24,25 
New smoking-specific and general items were translated into 
German using comparable methods, including forward/backward 
translation and lay person qualitative review, as documented by 
the Mapi Institute, Lyon, France.26 TQOLITv1 was administered to 
smokers at baseline, 3 months and 6 months and to former smok-
ers at 3  months (baseline) and 6  months. Completion of the sur-
vey was voluntary, although the research benefits were reiterated to 
participants as encouragement. Participants entered responses via an 
electronic data capture system (CRF Health, Helsinki, Finland) on 
a tablet device with a one-item-at-a-time interface. Clinic staff were 
given an instruction manual for the questionnaire14 to ensure that 
standards for administration of the survey were met, such as suitable 
environments for administration, recommended time for comple-
tion (10–20 minutes) and scripts to confirm respondents’ ability to 
read the questions and to introduce and conclude administration. If 
respondents had queries about items, staff could read the item aloud 
verbatim but could not interpret the wording.
Responses captured in the electronic data capture were trans-
ferred to an accredited drug development system (Statistical Analysis 
System [SAS] Institute Inc., Cary, NC). Data quality was assessed for 
completeness of data, defined as the percentage of items answered 
across multi-item scale scores (count of the total number of items 
with valid responses divided by the total number of possible 
responses for each scale).
Norm-based scoring algorithms were used to calculate domain 
scores. T-score transformations were performed to achieve a mean 
of 50 and SD of 10 in the US adult general population surveyed 
in 2011 for all new measures.14 Published scoring algorithms for 
the SF-36v2 were used to compute the physical component sum-
mary (PCS) and mental component summary (MCS) scores.27 For all 
general measures, higher scores indicate better health; for smoking-
specific symptom and smoking impact measures, higher scores indi-
cate worse health. For simplicity in this article, we refer to the best 
(healthiest) possible score in either direction as the ceiling. HRQoL 
scores were computed with licensed software (QualityMetric Health 
Outcomes Scoring Software 4.5 and John Ware Research Group Inc. 
QOLIX).
For all HRQoL measures, a three-point (0.30 SD unit) minimal 
important difference (MID) threshold was defined as meaningful.2,27 
This threshold was derived from various criteria, including self-
evaluations of change, correlations with improvements in disease 
markers, predictive studies of hospitalization and mortality2,28–30 and 
variations in rates of achieving MID thresholds across conditions in 
extensive clinical trial evidence.2
Statistical Analysis
Descriptive statistics for demographic variables were expressed as 
mean ± SD for continuous variables (age, average daily cigarette 
consumption in past 30 days and number of years of smoking) and 
as percentages for categorical variables (gender, employment, educa-
tion, ethnicity).
For TQOLITv1 scales and general measures, adjusted means for 
current and former smokers were calculated at study entry. To com-
pensate for data imbalances, a regression model was used for each 
measure that included smoking status (current or former), age and 
categorical variables.
Pearson product-moment correlations and estimated point-
biserial correlation coefficients were used to evaluate associations 
between pairs of measures (eg, symptoms and HRQoL impact) and 
between a measure and smoking status (eg, symptoms and current 
smoking status). It was hypothesized that favorably-scored general 
and unfavorably-scored smoking specific measures would be nega-
tively correlated. Stability of measures over time was evaluated with 
product-moment correlations between measures at baseline and 
3 months and 6 months for current smokers. Internal consistency 
reliability was estimated for all HRQoL measures with Cronbach’s 
coefficient alpha; a value of 0.70 or higher is recommended for 
group comparisons.31 Ceiling effects were examined separately for 
current and former smokers.
Exploratory analyses of changes from baseline to 6 months in 
RTP and control smokers included changes in least square means 
from repeated measures analysis of variance. For this assessment, a 
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model was determined by including categorical variables and smok-
ing group (RTP or control, time point and change in cigarette con-
sumption) and continuous variables for each smoking specific and 
general measure. Responder analysis (percentage of smokers with 
improved, unchanged or worsened scores, based on the MID thresh-
old of 0.30 SD units for all measures) and effect sizes (magnitude 
of change) were additionally used to explore change over time. The 
effect size was calculated for all smoking-specific and general meas-
ures separately for each smoking group by subtracting the baseline 
mean scores from 6 months mean scores and dividing by the SD of 
baseline scores of all participants. Effect size was evaluated as small 
(0.20), moderate (0.50), or large (0.80) according to the guidelines 
proposed by Cohen.32
Statistical analyses were performed with SAS (version 9.3) and 
SPSS (version 19). The significance level of the two-tailed tests was 
set at P < .05. Tukey’s adjustment was used to account for multi-
plicity in repeated measures analysis of variance and regression 
modeling.
Results
Participants
Baseline demographic characteristics are described for smokers 
including those in the RTP and control groups, and former smok-
ers (Supplementary Appendix 2). TQOLITv1 was completed by all 
enrolled current smokers (n = 128) at baseline and former smokers 
(n = 58) at 3 months. Data quality was good as determined by 100% 
completed item responses.
Reliability and Score Distributions
Reliability coefficients in current and former smokers exceeded 0.70 
for all measures (Table 1), an accepted standard for group compari-
sons. As expected for young healthy smokers, ceiling effects (percent-
age with best possible score) were substantial for smoking-specific 
HRQoL impact and measures of physical functioning for both cur-
rent and former smokers. However, no current smoker had the best 
score for smoking symptoms and only 5.2% of former smokers were 
at the ceiling on this measure (Table 1).
Comparison of new and SF-36v2 physical functioning meas-
ures indicated that the new measure substantially reduced the per-
centage of respondents with ceiling effects for current and former 
smokers combined (SF-36v2 59% vs. 35% for the new measure; 
Figure 1). However, the ceiling effect was not improved by the new 
GH-confidence measure when compared with the SF-36v2 GH 
measure (Table 1).
Validity
PCS and MCS scores did not differ significantly between current and 
former smokers at baseline (Table 1). However, the smoking-specific 
measures (symptoms and HRQoL impact) were significantly differ-
ent (both P < .001) in favor of former over current smokers. Former 
smokers also had significantly better scores than current smokers on 
the new physical function measure.
Significant correlations observed between all measures at base-
line were in the hypothesized direction for current and former 
smokers combined (Table 2). Correlations in current smokers were 
significant between smoking-specific impact and general measures as 
compared to weaker correlations for the same measures in former 
smokers. Significant correlations were seen between smoking-specific 
symptoms with the SF-36v2 MCS and the new physical function-
ing and GH-confidence measures in current smokers (Table  2). 
Additionally, smoking-specific HRQoL impact correlated sig-
nificantly with most measures among current smokers. In former 
smokers, correlations were generally weaker (Table  2), although 
significant correlations were seen between smoking symptoms and 
the SF-36v2 GH measure and the new GH-confidence measure. No 
significant correlations were seen for the smoking impact scale with 
other measures among former smokers.
Stability Over Time
All measures showed substantial stability from baseline to 
3 months and less stability at 6 months from baseline in current 
smokers (Table 3). Stability estimates were generally large enough 
to justify the use of baseline measures as covariates in analyses 
of cigarette consumption over time. Two noteworthy exceptions 
were the SF-36v2 MCS and GH scales, for which stability esti-
mates at 6 months dropped to 0.24 and 0.38 in current smokers 
(Table 3).
Comparison of HRQoL Scores in RTP and Control 
Smokers
Sixty one control smokers and 67 RTP smokers completed the study. 
Twelve smokers dropped out at 3 months of follow-up and two more 
dropped out at 6 months, with similar dropout rates in the control 
and RTP smoking groups. The reasons for dropouts included missed 
visits or noncompliance (n = 8), personal reasons (n = 2), adverse 
events (n = 3) and serious adverse events (n = 1).
Mean cigarette consumption was approximately 20 cigarettes 
per day at baseline in all smokers. After baseline, cigarette consump-
tion increased in both groups of smokers with mean consumption 
at 6 months reaching 28 cigarettes per day in the RTP group and 
29 cigarettes per day in the control group. Where consumption 
increased, this was reviewed with the individual and when appropri-
ate, the supply adjusted accordingly.
RTP smokers did not worsen in SF-36 PCS and MCS scores, 
smoking-specific HRQoL impact and new general measures 
when compared to control smokers (Figure  2), and these find-
ings were substantiated by the percentages who changed by the 
MID amount in the two groups (Supplementary Appendix 3). In 
control smokers, mean score change in smoking-specific HRQoL 
impact (baseline to 6 months: 58–62) was significant (P = .01), 
although the computed number of responders were relatively 
fewer than RTP smokers who had an insignificant worsening in 
smoking-specific HRQoL impact (Supplementary Appendix 3). 
Significant predictors for smoking-specific HRQoL impact were 
change in cigarette consumption, years of smoking, education 
and ethnicity.
Cohen’s effect size indicates small to moderate values for control 
smokers compared to small values for RTP smokers (Supplementary 
Appendix 4).
Discussion
HRQoL has gained importance in clinical research of various inter-
ventions and is expected to have a similar role in tobacco research. 
TQOLITv1, a new survey tool that integrates new smoking-specific 
with widely-used general HRQoL measures, and improves at least 
one of the latter (new physical function measure), is available in 
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English and German. In this study the German version of TQOLITv1 
was evaluated in cohorts of healthy current and former smokers in 
a cross-sectional analysis and over time. The improved psychomet-
ric properties of the new measures enhanced group comparisons, 
including confirming assumptions underlying the tool’s construction 
and scoring of scales and leading to satisfactory score reliability and 
validity.
The significant correlations seen between smoking-specific 
measures and general measures in current smokers as compared to 
weaker correlations among former smokers support the validity of 
TQOLITv1 in measuring the effects of current smoking. The pattern 
of significant correlations at baseline between general and smoking-
specific measures observed in this trial for the German translation is 
similar to the pattern observed for the English language version of 
TQOLITv1,33 suggesting that the results regarding construct validity 
are generalizable.
The new TQOLITv1 physical functioning measure raised the 
ceiling enough to improve analyses involving relatively well scor-
ing healthy smokers in comparison with the SF-36v2 physical 
function measure. The percentage of scores at the ceiling with the 
SF-36v2 was reduced from 59% to 35% with the new physical 
function measure. This extension in combination with the reduced 
ceiling effects for all the new smoking-specific measures, is likely 
to enhance the value of TQOLITv1 particularly for studies that 
focus on well smokers. The new GH-confidence measure was 
not expected to increase the measurement range over the legacy 
GH measure as it was intended to provide conceptual improve-
ments within the range measured by both. In addition, in light of 
the large ceiling effects observed in smokers for SF-36v2 social 
(50.7%) and role functioning (53.1%) measures in this study and 
in a previous study,14 improvements in items and response catego-
ries for these additional domains (analogous to those improved 
for physical functioning) warrant further testing to determine 
whether they also would better detect differences in outcomes 
between groups.
The stability of measures observed over the short term 
(3  months) in smokers and non-smokers was satisfactory to 
support their use in analyses of covariance. Stability of MCS 
dropped from baseline to 6 months in smokers due to a small 
number of outliers. Thus, it may not be as suitable in small, 
short-term studies of product effects performed with mixed 
model methods. Further evaluation is planned including another 
follow-up administration of TQOLITv1, 12 months after study 
completion.
All exploratory analyses with TQOLIT indicated a low mag-
nitude of HRQOL changes in RTP smokers. TQOLITv1 detected 
changes with intervention, a significant change in smoking spe-
cific HRQoL impact in those smoking conventional cigarettes. The 
Figure 1. Improved score distribution for new and SF-36 physical functioning measures. Note. Percentages may not add to 100 due to rounding.
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steeper declines seen in conventional than RTP smokers for other 
measures excluding smoking specific symptoms could potentially be 
due to an increase in cigarette consumption with the supply of free 
cigarettes. This limitation of the study design needs consideration in 
future studies.
The estimated effect sizes for smoking-specific HRQoL impact 
and SF-36v2 MCS were smaller in the RTP group than in control 
group, which suggests greater HRQoL impact for smokers of con-
ventional cigarettes. These exploratory findings need to be confirmed 
further in larger, more powerful studies that involve combustible 
RTPs, MRTPs (including alternative nicotine products such as e-cig-
arettes), or cessation with or without nicotine replacement therapies 
to confirm whether change of this degree or a greater degree could 
be detected. Likewise, the optimum times to observe changes in dif-
ferent domains of HRQoL as a result of individual behaviors such as 
the use of tobacco and/or nicotine products need to be determined.
The survey results reported are preliminary evaluations in a 
sample of very well-scoring healthy current and former smok-
ers. Therefore, the outcomes cannot be generalized to the general 
population. In measures that continue to show ceiling effects, 
the range of reliable scores should be extended to enable more 
accurate assessment of the impact on HRQoL in specific popula-
tions (eg, healthy young non-smokers and consumers of cigarettes, 
MRTPs or alternative nicotine products) at individual and popu-
lation levels. Further analysis of the HRQoL changes in relation 
to findings for other clinical parameters in this study measured at 
all-time point and in all groups such as biomarkers of exposure 
or effect is recommended to further confirm the end-point model 
underlying TQOLITv1.
Table 2. Correlations Between Measures at Baseline, Current, and Former Smokers
Group/measurea Smoking statusb Smoking symptoms Smoking impact
SF-36v2
New PFPCS MCS PF GH
Current and former smokers (n = 186)
 Smoking symptoms (−) 0.48**
 Smoking impact (−) 0.37** 0.36**
 SF-36v2 PCS (+) 0.01 −0.09 −0.09
 SF-36v2 MCS (+) 0.08 −0.14 −0.32** −0.07
 SF-36v2 PF (+) −0.09 −0.11 −0.28** 0.52** 0.20*
 SF-36v2 GH (+) 0.07 −0.15* −0.20** 0.60** 0.39** 0.35**
 New PF (+) −0.15* −0.30** −0.25** 0.40** 0.26** 0.61** 0.48**
 New GH confidence (+) 0.04 −0.25** −0.27** 0.36** 0.36** 0.32** 0.62** 0.41**
Current smokers (n = 128)
 Smoking symptoms (−)
 Smoking impact (−) 0.25**
 SF-36v2 PCS (+) −0.10 −0.17
 SF-36v2 MCS (+) −0.23** −0.43** −0.07
 SF-36v2 PF (+) −0.08 −0.33** 0.55** 0.22*
 SF-36v2 GH (+) −0.17* −0.26* 0.63** 0.33** 0.36**
 New PF (+) −0.28** −0.25** 0.44** 0.29** 0.63** 0.51**
 New GH confidence (+) −0.29** −0.37** 0.39** 0.32** 0.33** 0.60** 0.44**
Former smokers (n = 58)
 Smoking symptoms (−)
 Smoking impact (−) 0.10
 SF-36v2 PCS (+) −0.16 0.18
 SF-36v2 MCS (+) −0.12 −0.21 −0.05
 SF-36v2 PF (+) −0.06 0.10 0.47** 0.19
 SF-36v2 GH (+) −0.35** −0.15 0.53** 0.55** 0.39**
 New PF (+) −0.16 −0.00 0.32* 0.26* 0.50** 0.45**
 New GH confidence (+) −0.34** −0.03 0.30* 0.43** 0.30* 0.68** 0.37**
GH = general health; MCS = mental component summary; PCS = physical component summary; PF = physical functioning.
a(+) higher score indicates better health; (−) higher score indicates worse health.
bPoint-biserial correlation is statistically equivalent to a test of the difference between the two group means. Smoking status: current = 1, former = 0.
*P < .05; **P < .01.
Table 3. Correlations Between Baseline and Follow-Up Measures, 
Current Smokers
Measurea
Baseline and 
3 months (n = 116)
Baseline and 6 months 
(n = 114)
Smoking symptoms 
(−)
0.74 0.73
Smoking impact on 
HRQoL(−)
0.55 0.40
SF-36v2 PCS (+) 0.46 0.41
SF-36v2 MCS (+) 0.55  0.24*
SF-36v2 PF (+) 0.50 0.51
SF-36v2 GH (+) 0.66  0.38*
New PF (+) 0.72  0.54
New GH confidence 
(+)
0.50 0.41
GH = general health; HRQoL = health related quality of life; MCS = men-
tal component summary; PCS = physical component summary; PF = physical 
functioning. All correlations are significantly different from zero (P < .01) with 
the exception of MCS at 6-month follow-up which is P < .05.
a (+) higher score indicates better health; (−) higher score indicates worse health.
*6-month follow-up correlation significantly (P < .05) lower than 3-month 
follow-up correlation.
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Conclusions
The German translation of TQOLITv1 has psychometric proper-
ties that are sufficient for its use in studies of smoking populations. 
New TQOLIT smoking-specific HRQoL impact measures appear 
to be the most valid of those studied in discriminating between 
groups comprising individuals with different smoking behaviors. 
Particularly among well smokers, improvements in the range of 
measurement and reduced ceiling effects are likely to increase their 
sensitivity to changes over time. The improvements over SF-36v2 are 
likely to enhance evaluations of RTPs in well smoking populations.
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